Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2014-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research study is a Phase II clinical trial to test the efficacy of Olaparib in adult participants with recurrent/metastatic Ewing's Sarcoma following failure of prior chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

NCT01858168

Ewing Sarcoma Rhabdomyosarcoma

COMPLETED PHASE1

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

NCT01795430

Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) Ewing Sarcoma of Bone Extraosseous Ewing Sarcoma +4 more

WITHDRAWN NA

A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

NCT05275426

Ewing Sarcoma Ewing-Like Sarcoma

COMPLETED PHASE2

Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery

NCT01958580

Stage IA Uterine Sarcoma Stage IB Uterine Sarcoma Stage IC Uterine Sarcoma +8 more

TERMINATED NA

Cabozantinib With Topotecan-Cyclophosphamide

NCT04661852

Relapsed Ewing Sarcoma Refractory Ewing Sarcoma Relapsed Osteosarcoma +1 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary Objectives Evaluate the objective response rate of olaparib in adult patients with recurrent and/or metastatic Ewing's sarcoma following failure of conventional chemotherapy.

Secondary Objectives To evaluate the progression-free survival, overall survival, and safety of olaparib in this patient population (ie Number of Participants With Adverse Events). As an exploratory objective, the investigators will evaluate (in subjects who agree to an optional biopsy) differences in pre- and post-treatment tumor DNA alterations and differences in levels of protein and RNA expression related to PARP inhibition.

Study Design Potential subjects who discuss and sign the informed consent form will undergo screening studies. Eligible patients will administer olaparib and obtain restaging imaging studies after 6 and 12 weeks on study, and then every 8 weeks thereafter. Participants will remain on study drug until disease progression, onset of unacceptable toxicities, or subject withdraws consent.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ewing's Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Olaparib

400mg PO BID Continuous

Group Type EXPERIMENTAL

Olaparib

Intervention Type DRUG

400mg PO BID Continuous

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olaparib

400mg PO BID Continuous

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AZD 2281

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed Ewing's sarcoma
* Normal organ and bone marrow function
* Life expectancy of at least 16 weeks
* Not pregnant or breastfeeding
* Willing and able to comply with the protocol for the duration of the study
* Presence of measurable disease

Exclusion Criteria

* Involvement in the planning and/or conduct of ths study
* Previous enrollment in the present study
* Participation in another clinical study with an investigational product during the 21 days prior to first dose of study drug
* Previous exposure to any PARP inhibitor
* Receiving systemic chemotherapy or radiotherapy within 2 weeks of beginning study treatment
* Receiving prohibited classes of inhibitors of CYP3A4
* Persistent clinically significant toxicities caused by previous cancer therapy
* Known myelodysplastic syndrome or acute myeloid leukemia
* Symptomatic, uncontrolled brain metastases
* Major surgery within 14 days of starting study treatment
* Considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disorder or active, uncontrolled infection
* Unable to swallow orally administered medication or with gastrointestinal disorders likely to interfere with absorption of the study medication
* Known to be serologically positive for HIV and receiving antiretroviral therapy
* Known active Hepatitis B or C
* Known hypersensitivity to olaparib or any of the excipients of the product
* Uncontrolled seizures

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No